[go: up one dir, main page]

WO2010001409A3 - Composition de vaccin utile pour les infections par le virus de l'hépatite b et par le papillomavirus humain et son procédé de préparation - Google Patents

Composition de vaccin utile pour les infections par le virus de l'hépatite b et par le papillomavirus humain et son procédé de préparation Download PDF

Info

Publication number
WO2010001409A3
WO2010001409A3 PCT/IN2009/000333 IN2009000333W WO2010001409A3 WO 2010001409 A3 WO2010001409 A3 WO 2010001409A3 IN 2009000333 W IN2009000333 W IN 2009000333W WO 2010001409 A3 WO2010001409 A3 WO 2010001409A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
hepatitis
infections
preparing
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000333
Other languages
English (en)
Other versions
WO2010001409A2 (fr
Inventor
Krishna Murthy Ella
Kandaswamy Sumathy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bharat Biotech International Ltd
Original Assignee
Bharat Biotech International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP09773063.4A priority Critical patent/EP2288380B1/fr
Priority to RU2010154605/15A priority patent/RU2509570C2/ru
Priority to AU2009265095A priority patent/AU2009265095B2/en
Priority to BRPI0915076A priority patent/BRPI0915076A2/pt
Priority to NZ589755A priority patent/NZ589755A/xx
Priority to CN200980130450XA priority patent/CN102112152A/zh
Application filed by Bharat Biotech International Ltd filed Critical Bharat Biotech International Ltd
Publication of WO2010001409A2 publication Critical patent/WO2010001409A2/fr
Publication of WO2010001409A3 publication Critical patent/WO2010001409A3/fr
Priority to IL209806A priority patent/IL209806B/en
Anticipated expiration legal-status Critical
Priority to ZA2011/00051A priority patent/ZA201100051B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une composition de vaccin qui comporte des fusions chimériques des antigènes de papillomavirus humain avec des protéines virales ou bactériennes conférant une meilleure immunogénicité utile pour les infections par le virus de l'hépatite B et également par le papillomavirus humain (HPV).
PCT/IN2009/000333 2008-06-09 2009-06-09 Composition de vaccin utile pour les infections par le virus de l'hépatite b et par le papillomavirus humain et son procédé de préparation Ceased WO2010001409A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2010154605/15A RU2509570C2 (ru) 2008-06-09 2009-06-09 Вакцинная композиция, пригодная при инфекциях hpv и вирусом гепатита в, и способ ее получения
AU2009265095A AU2009265095B2 (en) 2008-06-09 2009-06-09 Vaccine composition useful for HPV and Hepatitis B infections and a method for preparing the same
BRPI0915076A BRPI0915076A2 (pt) 2008-06-09 2009-06-09 composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas.
NZ589755A NZ589755A (en) 2008-06-09 2009-06-09 Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
CN200980130450XA CN102112152A (zh) 2008-06-09 2009-06-09 适用于hpv和乙型肝炎感染的疫苗组合物以及其制备方法
EP09773063.4A EP2288380B1 (fr) 2008-06-09 2009-06-09 Composition de vaccin utile pour les infections par le virus de l'hépatite b et par le papillomavirus humain et son procédé de préparation
IL209806A IL209806B (en) 2008-06-09 2010-12-06 A vaccine composition for use against HPV and hepatitis b infections, and a method for its preparation
ZA2011/00051A ZA201100051B (en) 2008-06-09 2011-01-03 Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1404/CHE/2008 2008-06-09
IN1404CH2008 2008-06-09

Publications (2)

Publication Number Publication Date
WO2010001409A2 WO2010001409A2 (fr) 2010-01-07
WO2010001409A3 true WO2010001409A3 (fr) 2010-05-27

Family

ID=41466394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000333 Ceased WO2010001409A2 (fr) 2008-06-09 2009-06-09 Composition de vaccin utile pour les infections par le virus de l'hépatite b et par le papillomavirus humain et son procédé de préparation

Country Status (9)

Country Link
EP (1) EP2288380B1 (fr)
CN (1) CN102112152A (fr)
AU (1) AU2009265095B2 (fr)
BR (1) BRPI0915076A2 (fr)
IL (1) IL209806B (fr)
NZ (1) NZ589755A (fr)
RU (1) RU2509570C2 (fr)
WO (1) WO2010001409A2 (fr)
ZA (1) ZA201100051B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102614505A (zh) * 2011-11-25 2012-08-01 成都康华生物制品有限公司 一种包括酵母细胞中表达的hpv16型l1和e7靶抗原的嵌合蛋白疫苗及其制备方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102228698B (zh) * 2011-06-28 2013-12-18 广西医科大学附属肿瘤医院 Hpv58型治疗性复合基因疫苗及其构建方法
EA033242B1 (ru) * 2011-10-12 2019-09-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
WO2013168182A2 (fr) 2012-05-09 2013-11-14 Bharat Biotech International Limited Combinaisons de vaccin
WO2014103608A1 (fr) 2012-12-25 2014-07-03 一般財団法人化学及血清療法研究所 Vaccin contre l'infection par le hpv et/ou l'hépatite b contenant une protéine hpv/hbs chimérique à titre de principe actif
EP3586870A1 (fr) 2013-03-12 2020-01-01 The Trustees Of The University Of Pennsylvania Vaccins améliorés pour le papillomavirus humain et leurs procédés d'utilisation
EP2970409A2 (fr) 2013-03-15 2016-01-20 Bioven 3 Limited Protéines de synthèse à auto-assemblage
WO2017041083A1 (fr) 2015-09-04 2017-03-09 Inventprise, Llc Compositions de vaccin stabilisés de vlp
WO2018237115A2 (fr) 2017-06-23 2018-12-27 Pathovax Llc Particules de type virus chimériques et leurs utilisations en tant que redirecteurs spécifiques d'antigènes de réponses immunitaires
WO2019233415A1 (fr) * 2018-06-04 2019-12-12 厦门大学 Mutant de la protéine l1 du papillomavirus humain 39
US11389519B2 (en) 2018-06-11 2022-07-19 Inventprise, Llc Virus-like particle conjugates
EP3902527A4 (fr) 2018-12-27 2022-09-28 VerImmune Inc. Particules de type virus conjuguées et leurs utilisations en tant que redirecteurs immunitaires antitumoraux
CN114127094B (zh) * 2019-07-19 2024-04-26 神州细胞工程有限公司 嵌合的人乳头瘤病毒58型l1蛋白
CN112439059B (zh) * 2019-09-02 2022-02-08 怡道生物科技(苏州)有限公司 重组人乳头瘤病毒疫苗组合物及其用途
BR102019025802A2 (pt) * 2019-12-05 2022-01-18 Instituto Butantan Processo de produção de uma composição imunológica de dna profilática e terapêutica contra hpv e cânceres associados ao vírus, proteína híbrida, vetor de expressão, composição imunológica e seus usos
US11858964B2 (en) 2020-10-19 2024-01-02 Verimmune Inc. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017550A2 (fr) * 1999-09-07 2001-03-15 Smithkline Beecham Biologicals S.A. Nouvelle composition
WO2007095320A2 (fr) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Antigènes du papillomavirus humain, compositions de vaccin et méthodes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108226A1 (fr) * 2005-04-12 2006-10-19 The University Of Queensland Systeme de delivrance d’un vaccin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017550A2 (fr) * 1999-09-07 2001-03-15 Smithkline Beecham Biologicals S.A. Nouvelle composition
WO2007095320A2 (fr) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Antigènes du papillomavirus humain, compositions de vaccin et méthodes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TINDLE R W ET AL: "CHIMERIC HEPATITIS B CORE ANTIGEN PARTICLES CONTAINING B- AND TH-EPITOPES OF HUMAN PAPILLOMAVIRUS TYPE 16 E7 PROTEIN INDUCE SPECIFIC ANTIBODY AND T-HELPER RESPONSES IN IMMUNISED MICE", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 200, 1 January 1994 (1994-01-01), pages 547 - 557, XP002074501, ISSN: 0042-6822 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102614505A (zh) * 2011-11-25 2012-08-01 成都康华生物制品有限公司 一种包括酵母细胞中表达的hpv16型l1和e7靶抗原的嵌合蛋白疫苗及其制备方法

Also Published As

Publication number Publication date
IL209806B (en) 2018-10-31
EP2288380B1 (fr) 2020-06-03
IL209806A0 (en) 2011-02-28
AU2009265095B2 (en) 2014-09-11
ZA201100051B (en) 2011-10-26
WO2010001409A2 (fr) 2010-01-07
RU2509570C2 (ru) 2014-03-20
CN102112152A (zh) 2011-06-29
NZ589755A (en) 2013-04-26
AU2009265095A1 (en) 2010-01-07
RU2010154605A (ru) 2012-07-20
BRPI0915076A2 (pt) 2017-03-14
EP2288380A2 (fr) 2011-03-02

Similar Documents

Publication Publication Date Title
WO2010001409A3 (fr) Composition de vaccin utile pour les infections par le virus de l'hépatite b et par le papillomavirus humain et son procédé de préparation
IL203869A (en) Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method
WO2010149752A3 (fr) Nouvelles compositions
EP3266464A3 (fr) Thérapeutique à base de levure pour infection chronique par l'hépatite b
WO2007095320A3 (fr) Antigènes du papillomavirus humain, compositions de vaccin et méthodes
WO2010019262A3 (fr) Vaccin polyvalent
WO2012061815A3 (fr) Particules de type viral de glycoprotéine de la rage (vlp)
WO2008014521A3 (fr) Vaccins améliorés et leurs procédés d'utilisation
DK1951296T4 (da) Celleafledte viral vacciner med lave niveauer af restcelle-DNA
WO2007095318A3 (fr) antigenes de la grippe, compositions de vaccins et procedes associes
WO2007011904A3 (fr) Vaccins recombinants contre la grippe
WO2011015656A3 (fr) Composition pour le traitement d'une infection par le virus de l'hépatite b
WO2009012487A3 (fr) Pseudo-particules virales du virus chimère de la varicelle et du zona
CA2746228C (fr) Proteines f de vrs modifiees et leurs methodes d'utilisation
WO2007024941A3 (fr) Vaccin polyvalent
WO2008148104A8 (fr) Nouvelles vlp dérivées de cellules qui n'expriment pas une matrice virale ou une protéine du noyau
WO2006020071A3 (fr) Constructions vaccinales et combinaisons de vaccins conçues pour ameliorer l'etendue de la reaction immunitaire a diverses souches et variantes du vih
WO2010118424A3 (fr) Particules ressemblant au papillomavirus (vlp) comme vaccins à large spectre contre le papillomavirus humain (vph)
WO2007147529A3 (fr) Vaccin viral recombinant
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
WO2011153351A3 (fr) Vaccins vivants atténués inédits et vaccins sous-unitaires créés par recombinaison aléatoire de l'adn (« dna shuffling ») contre le virus du syndrome reproducteur et respiratoire porcin (vsrrp)
EP2568289A3 (fr) Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
BRPI0810951B8 (pt) proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
WO2008103819A3 (fr) Pseudo-particules virales (vlp) chimériques de la maladie de newcastle

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980130450.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09773063

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 209806

Country of ref document: IL

Ref document number: MX/A/2010/013362

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011512271

Country of ref document: JP

Ref document number: 589755

Country of ref document: NZ

Ref document number: 2009265095

Country of ref document: AU

Ref document number: 2009773063

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010122081

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009265095

Country of ref document: AU

Date of ref document: 20090609

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010154605

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0915076

Country of ref document: BR

Free format text: APRESENTE O COMPLEMENTO DO TEXTO (LISTAGEM DE SEQUENCIA BIOLOGICA) EM PORTUGUES, ADAPTADO A NORMA VIGENTE, DO PEDIDO CONFORME DEPOSITO INTERNACIONAL INICIAL, EM FORMATO ELETRONICO, CONFORME DETERMINAM A RESOLUCAO INPI-PR NO 77/2013 DE 18/03/2013, ART. 5O E 7O, A RESOLUCAO INPI-PR NO 81/2013 DE 28/03/2013 E A RESOLUCAO INPI-PR NO 228/2009 DE 11/11/2009

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0915076

Country of ref document: BR

Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 2364 DE 26/04/2016 SOLICITA-SE QUE A EXIGENCIA SEJA RESPONDIDA CORRETAMENTE, NUM PRAZO DE 60 DIAS, POR MEIO DA GRU CODIGO 207 ESPECIFICA PARA ESSE TIPO DE SERVICO.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: PI0915076

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: PI0915076

Country of ref document: BR

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0915076

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101209